Minerva Neurosciences, Inc (NERV)

Etorro trading 970x250
Minerva Neurosciences, Inc (NERV) Logo

About Minerva Neurosciences, Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Address: 1601 Trapelo Road, Waltham, MA, United States, 02451

Minerva Neurosciences, Inc News and around…

Latest news about Minerva Neurosciences, Inc (NERV) common stock and company :

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Invest In Growth?
01 Dec, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates
08 Nov, 2021 Yahoo! Finance

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

12 Health Care Stocks Moving In Monday's Pre-Market Session
08 Nov, 2021 FinancialContent

Gainers Autolus Therapeutics (NASDAQ:AUTL) stock rose 21.04% to $6.73 during Monday's pre-market session. The ...

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
08 Nov, 2021 Yahoo! Finance

Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended September 30, 2021. Roluperidone Update On November 3, 2021, the Company announced that the U. S. Food and Drug Administration (FDA) denied

26 Stocks Moving in Monday's Pre-Market Session
08 Nov, 2021 FinancialContent

Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science ...

Earnings Scheduled For November 8, 2021
08 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 ...

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
03 Nov, 2021 Yahoo! Finance

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U. S. Food and Drug Administration (FDA) has denied the company’s request for a pre-NDA meeting for roluperidone and responded that a Type C guidance meeting would be more appropriate to discuss the evidence for use of roluperidone as monotherapy. S

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
01 Nov, 2021 Yahoo! Finance

Management to Host Conference CallWALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the third quarter of 2021 on Monday, November 8, 2021. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these r

12 Health Care Stocks Moving In Monday's After-Market Session
25 Oct, 2021 FinancialContent

Gainers Medpace Hldgs (NASDAQ:MEDP) shares moved upwards by 10.73% to $208.6 during Monday's after-market session. The market value ...

Minerva Neurosciences Announces Promotion of Geoff Race to President
11 Oct, 2021 Yahoo! Finance

Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Geoff Race, current Executive Vice President, Chief Financial Officer and Chief Business Officer of Minerva, has been promoted to President

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
05 Oct, 2021 FinancialContent

Gainers Ocugen (NASDAQ:OCGN) shares moved upwards by 11.11% to $7.5 during Tuesday's pre-market session. The market ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

15 Stocks Moving in Friday's Pre-Market Session
01 Oct, 2021 FinancialContent

Gainers Progenity, Inc. (NASDAQ: PROG) rose 33% to $2.02 in pre-market trading after jumping over 40% on Thursday. Iterum ...

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
30 Sep, 2021 FinancialContent

Minerva Neurosciences Inc(NASDAQ: NERV) announcedresults from a bioequivalence studycomparing roluperidone ...

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
30 Sep, 2021 FinancialContent

Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration

Analysts Forecast 70% Gains Ahead For LOPX
28 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Low Priced Stock ETF ETF (LOPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $16.41 per unit.

Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options
27 Sep, 2021 Yahoo! Finance

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

A Few names on TOP of my watchlist for the coming week
26 Sep, 2021 FinancialContent
22 Stocks Moving in Friday's Pre-Market Session
24 Sep, 2021 FinancialContent

Gainers Focus Universal Inc. (NASDAQ: FCUV) rose 42% to $15.24 in pre-market trading. The company’s shares jumped around 65% ...

3 Downgraded Stocks to Sell in a Shaky Market
17 Sep, 2021 FinancialContent

Over the last two weeks, the market has been steadily moving lower. There are increasing signs of economic stress in terms of supply chain issues, coronavirus case counts continuing to rise, and signs that the consumer may be tapped out.

Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
08 Sep, 2021 FinancialContent

Dr. Jay Saoud, Head of Research & Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned submission of a New Drug Application (NDA) for Minerva’s lead program, roluperidone

How The Parts Add Up: LOPX Targets $16
24 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Low Priced Stock ETF ETF (LOPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $15.65 per unit.

Papyrus Therapeutics Inc. Announces Additions to Its Board of Directors
17 Aug, 2021 FinancialContent

Papyrus Therapeutics Inc. announces additions to its Board of Directors.

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
04 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
03 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Monday
02 Aug, 2021 FinancialContent

Monday morning, 34 companies reached new 52-week lows. Things to Consider: Las Vegas Sands (NYSE:LVS) was ...

Minerva Neurosciences, Inc (NERV) is a NASDAQ Common Stock listed in , ,

970x250